Bloomberg Businessweek

An Alzheimer’s Vaccine Hints of Promise

United Neuroscience’s small Phase II trial appears to have cleared a decades-old hurdle

For two decades, biotech companies trying to tackle Alzheimer’s disease have had little success. While vaccines have often shown promise for certain patients, they’ve come with devastating side effects for others—brain swelling, for example—because researchers haven’t been able to reliably keep patients’ immune systems from kicking into overdrive when exposed to the vaccines. Now, a four-year-old Dublin startup believes it may be on to something.

To be clear, United Neuroscience Inc. hasn’t solved Alzheimer’s yet, nor has it claimed to. But previously unreported results from a small, recent United clinical

You're reading a preview, sign up to read more.

More from Bloomberg Businessweek

Bloomberg Businessweek7 min readPolitics
Martyrdom in The Time of Xi
• The death of a persecuted whistleblower is the gravest political challenge to China’s Xi Jinping yet
Bloomberg Businessweek3 min read
TLC’s Thriving Franchise
Like every successful reality TV show, 90 Day Fiancé begins with an intriguing concept: Can a blossoming romance survive the harsh rigors of the American immigration system? From there, of course, it descends into spellbinding acrimony. In each hour
Bloomberg Businessweek12 min read
When Trump Doesn’t Love You Back
John Hritz, president and chief executive officer of JSW Steel USA Inc., put on a big smile and a Texas flag pin for his television spot on Fox Business in March 2018. “It’s a special day,” he told his host, then told her again: “It’s a special day.”